anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the biotechnology and the medical field and discloses a new human epididymal specific expression sperm binding protein HEL-40 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-40 protein and provides a recombinant expression vector which carries a DNA sequence used for encoding the protein. The protein is located at the back region of the head of a mature sperm, and an RT-PCR result indicates that the gene has higher expression level at the body part of an epididymis, a testis and a liver and has no expression in other tissues. A band of about 37 KD is detected in the body part of the epididymis by using Western blot. The HEL-40 protein can be used as a target protein for developing an immunological contraceptive and clinically diagnosing and treating male infertility. A method for detecting a corresponding gene or protein based on development of the HEL-40 protein can be widely used for the research field of reproductive medicine.
The invention relates to a medicament for treating meniscus injury. The common symptoms of the meniscus injury are obvious rtauma history, knee-joint swelling and pain, knee-joint interlocking, knee-joint dislocation, amyotrophy, clicking of joint during the movement process, positive knee-joint rotation test and positive grinding test. The meniscus injury has no special X-ray manifestation and can be clearly diagnosed by MRI (Magnetic Resonance Imaging). Through long-term research and clinical verification, the inventor finally finds a traditional Chinese medicine oral medicament with a better curative effect for treating the meniscus injury; the dosage of the components of the medicament disclosed by the invention is given through a plurality of tests of the inventor; and the optimum ratio (in parts by weight) of the medicines of medicament for treating meniscus injury is as follows: 10 parts of Chinese angelica, 6 parts of ligusticum wallichii, 9 parts of angelica roots, 12 parts of teasel roots, 5 parts of red flowers, 12 parts of dried rehamnnia roots, 9 parts of radix achyranthis bidentatae, 9 parts of barks of tree peony and 9 parts of barks of eucommia. The medicines are combined, so that the effects of the medicines generate a synergistic effect. And therefore, the medicament for treating meniscus injury has the effects of promoting blood circulation to remove blood stasis, dredging collaterals, jointing bones, stopping pains and strengthening muscles and bones, and can be used for effectively treating the meniscus injury.
Medical abortion represents an important alternative to surgical methods for termination of early pregnancy. In Mexico City, abortion is legal on request up to 12 weeks of gestation; however, medical abortion is currently only offered up to 10 weeks at Marie Stopes Mexico clinics. The World Health Organization guidelines state that medical abortion drugs may be used to terminate pregnancy up to a gestational age of 24 weeks in clinical settings, with recommended regimens differing by gestational age. However, data are lacking on the safety and effectiveness of home-based medical abortion regimens for pregnancy terminations between \>9 and ≤12 weeks' gestation. Investigators propose a prospective cohort study with women between 8 and ≤9 weeks and \>9 and ≤12 weeks of pregnancy at Marie Stopes Mexico clinics to compare the effectiveness, safety, and acceptability of mifepristone followed by home-based misoprostol use in these two gestational age groups. The information from this study will inform policy and practice guidelines in Mexico City and potentially other locations by providing evidence on the safety, effectiveness, and acceptability of home-use of medical abortion between \>9 and ≤12 weeks of gestation.
The second group will receive intraligamentary injections of 2% lidocaine with 1:80 000 epinephrine plus tramadol hydrochloride (50 mg, 1:1 v/v ratio). The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
PURPOSE:To obtain the title preventive and treating agent, containing live or dead microbial cells of Clostridium sp. strain NIP1201 or a cultivation filtrate thereof as an active ingredient, having high safety and capable of exhibiting excellent effects. CONSTITUTION:A preventive and treating agent containing live or dead microbial cells of Clostridium sp. strain NIP1201 (FERM P-9570) which is a Gram-positive, strict anaerobic and sporulating bacillus or a cultivation filtrate thereof as an active ingredient. The above-mentioned live microbial cells are capable of propagating in the digestive tracts after administration and intracellularly or extracellulary producing the active ingredient. The active ingredient is also contained in the cultivation filtrate obtained by cultivating the microorganism or dead microbial cells. The afore-mentioned preventive and treating agent is orally administered and the dose thereof is within the range of 10<6>-10<10> cells expressed in terms of viable cell number per kg body weight.
Compounds, pharmaceutical compositions, and methods for treatment of microbial infections are provided. The compounds can potentiate the therapeutic effects of one or more antimicrobial agents when co-administered. The compounds have antivirulence properties. Pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier are provided. The pharmaceutical composition can further include at least one antibiotic, such as, Gentamicin, amikacin, kanamycin, neomycin, spectinomycin, neamine or any combination thereof. The compounds and compositions can be used to treat or prevent microbial infections.
An injectable hydrogel for drug delivery is provided having a first component of repeating protein domains, and a second component cross-linked with the first component. The protein domain in the repeating protein domains is a WW protein sequence interspersed with hydrophilic protein sequences (repeats ranges from 2 to 10). The second component is an inter-bilayer crosslinked multilamellar vesicle. The vesicle is capable of containing drug cargo and eluting the drug cargo. The vesicle is derived from a first lipid and a second lipid. The surface of the vesicle has tethers, which are cross-linked with protein domains of the first component. Control over elution rate of drug cargo is accomplished through stabilization of the vesicles. Gelation occurs in a simple and rapid mixing of the two components without the necessity of additional crosslinking stimuli. Tuning of elution rate is achieved while not losing injectability. Bioresorbable components are used.
Combined nutrition and exercise interventions potentially improve protein-energy wasting/malnutrition-related outcomes in patients with chronic kidney disease (CKD). The aim was to systematically review the effect of combined interventions on nutritional status, muscle strength, physical performance and QoL. MEDLINE, Cochrane, Embase, Web of Science and Google Scholar were searched for studies up to the date of July 2023. Methodological quality was appraised with the Cochrane risk-of-bias tool. Ten randomized controlled trials (nine publications) were included (334 patients). No differences were observed in body mass index, lean body mass or leg strength. An improvement was found in the six-minute walk test (6-MWT) (n = 3, MD 27.2, 95%CI [7 to 48], p = 0.008), but not in the timed up-and-go test. No effect was found on QoL. A positive impact on 6-MWT was observed, but no improvements were detected in nutritional status, muscle strength or QoL. Concerns about reliability and generalizability arise due to limited statistical power and study heterogeneity of the studies included.
This study will be a first-in-human study evaluating the safety and tolerability of FWD1509 MsOH in subjects with advanced NSCLC, when FWD1509 MsOH is administered once daily as a single agent. FWD1509 MsOH is an oral TKI (Tyrosine Kinase Inhibitor) that blocks the function of tyrosine kinase. TKIs such as gefitinib, erlotinib or afatinib are recommended as the first-line therapy for EGFR mutated (exon 19 deletions or L858R point mutations in exon 21) NSCLC patients. However, the majority (\>50%) of patients will develop acquired resistance after initially responding to gefitinib or erlotinib due to the occurrence of secondary mutations (mostly T709M) in EGFR. Osimertinib was subsequently developed to such secondary mutations, but for EGFRex20ins mutations, on which there is still no effective therapies focusing. FWD1509 MsOH is new generation EGFR-TKI targeting EGFR mutations such as exon 19 deletion, L858R substitution as well as T790M mutations. In particular, FWD1509 MsOH targets the EGFRex20ins mutation in NSCLC. In addition to activity against EGFR mutations, FWD1509 MsOH is also active against a variety of HER2 mutations.

The development of FWD1509 MsOH at this stage is mainly focused on treatment of NSCLC tumors with EGFRex20ins mutations, followed by further exploration against other targets.
Acute asthma exacerbations and viral-induced wheeze are common presenting complaints on one general paediatric ward in a tertiary children's hospital in England. An inhaled beta 2 agonist, such as salbutamol, is the first-line treatment for these children and young people and they have frequent clinician reviews for salbutamol weaning before discharge. However, the informal salbutamol weaning practices used by nurses, as well as challenges in the recruitment and retention of paediatric trainee doctors, led to the development of a nurse-led salbutamol weaning pathway as a quality improvement project. Twelve nurses completed the associated nurse-led salbutamol weaning training, education and competency package and subsequently completed a questionnaire exploring their perceptions of the effect of the training package and pathway. After the training, all respondents reported feeling more confident in assessing the salbutamol requirements of children with wheeze. All of the respondents also felt that the introduction of the pathway and training would improve patient care and the confidence of children and young people, parents and carers in nurses' ability to assess children's salbutamol requirements. Time constraints were identified as a potential barrier to implementation of the pathway.
The objective of this project is to examine the effectiveness of a community health worker (CHW) intervention at addressing glycemic control among Latinos with poorly controlled Type 2 diabetes. Our group has worked with a promising model of intervention that utilizes CHW's based at one of our major community partners. Pilot data from this program has shown clinically significant prepost test improvements in HgA1C. Using the Chronic Care Model as an overarching framework, the study design of NOCHOP is a randomized controlled trial of 360 Latinos, mostly of Caribbean descent, aged 35-70 years with HgA1C \>=8.0. At a minimum, subjects in the intervention group will receive four home visits, ten group level visits and monthly phone calls by CHWs based at Alianza. The control groups will receive three separate mailings of bilingual diabetes health education materials. The primary outcome is glycemic control at 12month follow up, as measured by HgA1c. The secondary outcomes are changes in cholesterol and blood pressure (BP). We will also collect exploratory data on potential mechanisms through which our intervention resulted in hypothesized improvements including medication adherence, medication Intensification, diet and exercise. If successful, our project will make an important contribution to ongoing national and local debates about the sustainability of CHW programs. In particular, data from this study would be extremely useful for local Medicaid managed care plans who have expressed strong interests in data from rigorously designed clinical trials addressing the role of CHWs in delivering culturally appropriate and effective diabetes care.
BACKGROUND: To identify the differences of lumbar lordosis (LL) and sacral slope (SS) angles between two types of postoperative lumbar disc re-herniation, including the recurrence of same level and adjacent segment herniation (ASH).
METHODS: We searched the medical records of lumbar disc herniation (LDH) patients with re-herniation with complete imaging data (n = 58) from January 1, 2013 to December 30, 2020 in our hospital. After matching for age and sex, 58 patients with LDH without re-herniation from the same period operated by the same treatment group in our hospital were served as a control group. Re-herniation patients were divided into two groups, same-level recurrent lumbar disc herniation group (rLDHG) and adjacent segment herniation group with or without recurrence (ASHG). The preoperative, postoperative and one month after operation LL and SS were measured on standing radiographs and compared with the control group by using t-test, ANOVA, and rank-sum test. Next, we calculated the odds ratios (ORs) by unconditional logistic regression, progressively adjusted for other confounding factors.
RESULTS: Compared with the control group, the postoperative LL and SS were significantly lower in LDH patients with re-herniation. However, there were no differences in LL and SS between ASHG and rLDHG at any stage. After progressive adjustment for confounding factors, no matter what stage is, LL and SS remained unassociated with the two types of re-herniation.
CONCLUSIONS: Low postoperative LL and SS angles are associated with degeneration of the remaining disc. Low LL and SS may be independent risk factors for re-herniation but cannot determine type of recurrence (same or adjacent disc level).
FIELD: chemistry. ^ SUBSTANCE: invention can be used to prepare dispersions of titanium dioxide nanoparticles suitable for photocatalytic coatings on surfaces, for photocatalytic disinfection of gases and liquids and for preparing cosmetic compositions with high degree of skin protection from the sun. The method of preparing dispersions of anatase nanoparticles involves the following steps: i) reaction of titanium alkoxide with a complexing solvent selected from a group consisting of ethylene glycol, diethylene glycol or polyethylene glycol; ii) distillation of the solution obtained at step i) to a small volume; iii) addition of water of to the solution obtained at step ii) together with the above mentioned complexing solvent and one or more polycondensation inhibitors, and then heating the reaction mixture with a reflux condenser. The polycondendation inhibitor consists of a mixture which contains at least one inorganic acid and one organic acid. The amount of inorganic acid ranges from 0.1 to 10% of the total volume of the reaction mixture and the amount of organic acid ranges from 1 to 20 vol %. ^ EFFECT: invention increases stability of dispersions of anatase nanoparticles. ^ 3 dwg, 2 tbl, 12 ex
The invention provides pharmacophores for use in the design, screening and identification of inhibitors of CYP17A1 and CYP19A1 enzymes. A preferred pharmacophore has a spatial arrangement of atoms as shown in the accompanying Figure 1, wherein:  A represents hydrogen bond acceptors;  D represents hydrogen bond donors; and  R represents aromatic rings. Compounds conforming to the preferred pharmacophore are provided for use as medicaments in the treatment of cancer, especially prostate cancer and breast cancer. By way of example, these compounds include N-(4-ethylphenyl)-5-(2-hydroxy-5-methoxybenzoyl)-2-imino-2H-pyran-3-carboxamide and 2-(4-sulfamoylphenoxy) ethyl 2-amino-3-methylbenzoate. Also provided are methods for the treatment of prostate cancer and breast cancer using the compounds of the invention as well as their salts, solvates, hydrates, primary metabolites and prodrugs. Methods of inhibiting CYP17A1 and CYP19A1, and hence of inhibiting androgen activity in a subject, are disclosed. The invention also provides processes for designing, screening and identifying compounds which can inhibit CYP17A1 and CYP19A1.
In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.

LEVAQUIN® exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of LEVAQUIN®: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.
Although the exact mode of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced.

Additionally, tretinoin acts by modulating the proliferation and differentiation of epidermal cells. These effects are mediated by tretinoin's interaction with a family of nuclear retinoic receptors. Activation of these nuclear receptors causes changes in gene expression. The exact mechanisms whereby tretinoin-induced changes in gene expression regulate skin function are not understood.
Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
Provided herein are nanofibers and processes of preparing nanofibers. In some instances, the nanofibers are metal and/or ceramic nanofibers. In some embodiments, the nanofibers are high quality, high performance nanofibers, highly coherent nanofibers, highly continuous nanofibers, or the like. In some embodiments, the nanofibers have increased coherence, increased length, few voids and/or defects, and/or other advantageous characteristics. In some instances, the nanofibers are produced by electrospinning a fluid stock having a high loading of nanofiber precursor in the fluid stock. In some instances, the fluid stock comprises well mixed and/or uniformly distributed precursor in the fluid stock. In some instances, the fluid stock is converted into a nanofiber comprising few voids, few defects, long or tunable length, and the like.
Participants assigned to the PAS group will proceed through the weight management program provided by the center and will be given 4 weeks of 24-hour access to the PAS intervention during data collection for this study. The login credential for PAS participants will provide access to both the PAS intervention and to a secure website to complete data collection at W1, W2, and W3.
The invention discloses a three-dimensional display device for nodules, which comprises: the system comprises an information acquisition module, a nodule position extraction module, a coordinate conversion module and a nodule three-dimensional display module. The device can obtain and analyze the nodule detection result in the JSON format to obtain nodule information and section distance information. Then, a nodule position is extracted from the nodule information, and the solution position is converted into standard coordinates by using the slice distance information. The standard coordinates are converted to screen coordinates based on the reality settings. Thus, a three-dimensional model of the region of interest with the identification solution drawn at each bit plane can be displayed on the screen. Therefore, a doctor can accurately know the specific conditions of the nodule on different position surfaces by looking up the three-dimensional model, and convenience is provided for the doctor to diagnose and treat the nodule. The invention also discloses a three-dimensional display device for the nodule, which has corresponding technical effects.
A system for surveying nursing quality of nursing units at multiple healthcare facilities via a network includes a first Web client, a second Web client, a third Web client, a database, and a Web server. A staff member of a first nursing unit of a first healthcare facility is prompted for a type of data relating to a nursing quality indicator via the first Web client. A staff member at a second nursing unit of a second healthcare facility is prompted for the same type of data via the second Web client. Data elements are transmitted to a Web server and stored in a database. If the first nursing unit and the second nursing unit are of the same type, the data elements are compared. Results from the comparison are listed based on unit type and healthcare facility. Results are transmitted from the Web server to a third client for display.
BACKGROUND: HPV is responsible for most cervical, oropharyngeal, anal, vaginal, and vulvar cancers. The HPV vaccine has decreased cervical cancer incidence, but only 49% of Texas adolescents have initiated the vaccine. Texas shows great variation in HPV vaccination rates. We used geospatial analysis to identify areas with high and low vaccination rates and explored differences in neighborhood characteristics.
METHODS: Using Anselin's Local Moran's I statistic, we conducted an ecological analysis of hot and cold spots of adolescent HPV vaccination coverage in Texas from 2017 to 2021. Next, we utilized a Mann-Whitney U test to compare neighborhood characteristics of vaccination coverage in hot spots versus cold spots, leveraging data from the Child Opportunity Index (COI) and American Community Survey.
RESULTS: In Texas, there are 64 persistent vaccination coverage hotspots and 55 persistent vaccination coverage cold spots. The persistent vaccination coverage hot spots are characterized by ZIP codes with lower COI scores, higher percentages of Hispanic residents, higher poverty rates, and smaller populations per square mile compared to vaccine coverage cold spots. We found a more pronounced spatial clustering pattern for male adolescent vaccine coverage than we did for female adolescent vaccine coverage.
CONCLUSION: In Texas, HPV vaccination coverage rates differ depending on the community's income level, with lower-income areas achieving higher success rates. Notably, there are also gender-based discrepancies in vaccination coverage rates, particularly among male adolescents. This knowledge can aid advocates in customizing their outreach initiatives to address these disparities.
Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.